|
Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer Clinical research trials and Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer. Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer clinical trial. Human subjects frequently get the finest healthcare available for their Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer  Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer
Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer
For Condition: basal cell carcinoma of the skin,recurrent skin cancer
Status: Suspended
Sponsor(s): Roswell Park Cancer Institute , National Cancer Institute (NCI)
Synopsis: RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by cancer cells and, when exposed to light, become active and kill the cancer cells. PURPOSE: Phase I trial to study the effectiveness of photodynamic therapy with HPPH in treating patients who have basal cell skin cancer.
Details: OBJECTIVES: - Determine the safety of HPPH used in photodynamic therapy in patients with basal cell skin cancer. - Determine the drug dose, light dose, and treatment interval combinations that do not produce excessive toxicity to normal skin but effect tumor response in these patients treated with this regimen. - Determine the length of time for cutaneous photosensitivity in these patients treated with this regimen. - Determine the plasma clearance rates for HPPH in these patients. - Determine the best combination of treatment parameters for a phase II study. OUTLINE: This is a dose-escalation study. Patients receive HPPH IV on day 1. Patients undergo phototherapy on days 2-3. Cohorts of 2-6 patients receive escalating doses of HPPH and phototherapy to determine the minimum erythemal dose (MED). The MED is defined as the dose combination of HPPH and laser light preceding that at which at least 1 patient experiences grade 3 or worse toxicity or at which at least 2 patients experience grade 1 or worse toxicity. Patients are followed daily for 4 days, at week 1, and at months 1, 3, 6, 12, and 24. PROJECTED ACCRUAL: A total of 4-25 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed non-morpheaform basal cell skin cancer - Primary disease OR - Recurrent disease after prior therapy (e.g., surgical excision, electrodesiccation, cryosurgery, or radiotherapy) - At least 4 lesions, no greater than 2 cm in diameter and no greater than 5 mm in depth - No lesions located on the eyelid, nose, ear, periauricular area, genitals, or digits, or any other lesions thought to be deep and/or aggressive PATIENT CHARACTERISTICS: Age: - Over 18 Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - WBC at least 2,000/mm^3 - Platelet count at least 120,000/mm^3 Hepatic: - PT/PTT no greater than 1.5 times upper limit of normal (ULN) - Bilirubin no greater than 3.0 mg/dL - Liver enzymes no greater than 2 times ULN - No impaired hepatic function Renal: - No impaired renal function Cardiovascular: - No myocardial infarction within the past 6 months Other: - No porphyria - No known hypersensitivity to porphyrins - No systemic lupus erythematosus - No history of positive antinuclear antibody - No history of degenerative disease of the retina - No xeroderma pigmentosum - No pancreatic disease - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - At least 3 months since prior combination doxorubicin and radiotherapy Endocrine therapy: - Not specified Radiotherapy: - See Disease Characteristics - See Chemotherapy Surgery: - See Disease Characteristics
Total Enrollment:
Location and Contact Information:
Overall Study Official:
AllanOseroff, Study Chair, Roswell Park Cancer Institute
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
United States
Additional Information:
Study ID Numbers: CDR0000068696; RPCI-DS-95-34,NCI-G01-1953
Study Start Date:
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00017485
Other Basal Cell Carcinoma Of The Skin Studies:
1. Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer
Related Studies:
Other basal cell carcinoma of the skin Clinical Trials
Other New York Clinical Trials
Other Buffalo Clinical Trials
Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer
|
|
|
|
|
|
|
|
